Rycarfa vet. (25 - 50 kg)

10 x 10 pc

Tablet

Active substance

Carprofen : 100 mg

ATC code

QM01AE91 Carprofen

QM01AE Propionic acid derivatives

QM01A Antiinflammatory and antirheumatic products, non-steroids (NSAIDs)

QM01 Antiinflammatory and antirheumatic products

QM Musculo-skeletal system

Species

Dogs.

Indications

Reduction of inflammation and pain caused by musculoskeletal disorders and degenerative joint disease. As a follow up to parenteral analgesia in the management of post-operative pain.

Dose to be administered and administration route

For oral use.

2 to 4 mg carprofen per kg bodyweight per day.

An initial dose of 4 mg carprofen per kg bodyweight per day given as a single daily dose or in two equally divided doses may, subject to clinical response, be reduced after 7 days to 2 mg carprofen/kg bodyweight/day given as a single dose. In order to adjust the dosage, the tablets can be divided into two equal parts. Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision.

To extend analgesic and anti-inflammatory cover post-operatively, parenteral preoperative treatment may be followed with Carprofen tablets at 4 mg/kg/day for up to 5 days.

To ensure a correct dosage, body weight should be determined as accurately as possible.

Adverse reactions

Dogs:

Rare

(1 to 10 animals / 10 000 animals treated):

Renal disorder.

Hepatic disorder^¹.

Undetermined frequency (cannot be estimated from the available data):

Vomiting^², loose stool², diarrhoea², blood in faeces², appetite loss², lethargy ².

¹Idiosyncratic reaction.

² Transient. Generally, occur within the first treatment week and in most cases disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, use of the veterinary medicinal product should be stopped and the advice of a veterinarian should be sought.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.